PROVIDENCE, RI — August 13, 2025 — Leads & Copy — KIFFIK Biomedical, Inc. announced the appointment of Rene Veloso as Chief Investment Officer and Dr. Reginald Swift as fractional Chief Scientific Officer. Veloso will lead investor relations and secure funding for clinical operations. Swift, CEO of Rubix Life Sciences, will shape KIFFIK’s clinical strategy.
According to KIFFIK Biomedical CEO George Cagna, these additions strengthen the leadership team and support the company’s growth. Veloso’s experience includes leading M&A activities at Locust Walk Partners, LLC. Swift’s expertise in aptamer-based precision medicine will enhance research and development, building on the strategic partnership between KIFFIK and Rubix LS.
KIFFIK Biomedical focuses on interstitial fluid (ISF)-based diagnostics. Their KIFFIK EXP platform provides non-invasive solutions for oncology and therapeutic monitoring.
Contact: Michael Lauer, michael@mdlcomms.com
Source: KIFFIK Biomedical
